AD is characterized by the presence of amyloid-beta (Aβ) plaques and tau pathology, with estimates suggesting that comorbid AD pathology occurs in about 48–88% of DLB cases (8, 85–89) while up to 60% of AD patients will have comorbid Lewy body pathology (90). Here, MAPT is linked to Alzheimer disease.